Pentameric models as alternative molecular targets for the design of new antiaggregant agents

Current Protein and Peptide Science

Volumn 17, Issue 2, 2016, Pages 156-168

  Barrera Guisasola, Exequiel E ^a,b   Gutierrez, Lucas J ^a,c   Andujar, Sebastián A ^a,b   Angelina, Emilio ^b,c   Rodríguez, Ana M ^a,b   Enriz, Ricardo D ^a,b  

^a UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

^b IMIBIO SL ^*  (Argentina)

^c UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

Author keywords

Antiaggregant compounds; MD simulations; Mimetic peptides; Molecular target; Pentameric model; Virtual screening

Indexed keywords

AMYLOID BETA PROTEIN; ANTIAGGREGANT AGENT; CHEMICALS AND DRUGS; UNCLASSIFIED DRUG; PROTEIN AGGREGATE;

ARTICLE; COLLAGEN FIBRIL; CONFORMATIONAL TRANSITION; DRUG DESIGN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN INTERACTION; SIMULATION; STRUCTURAL PROTEOMICS; ALZHEIMER DISEASE; CHEMISTRY; COMPUTER INTERFACE; COMPUTER SIMULATION; HUMAN; MOLECULAR MODEL; PATHOLOGY; PROTEIN DATABASE; RECEIVER OPERATING CHARACTERISTIC;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; COMPUTER SIMULATION; DATABASES, PROTEIN; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PROTEIN AGGREGATES; ROC CURVE; USER-COMPUTER INTERFACE;

EID: 84957949341     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203716666151102104926     Document Type: Article

References (88)

1. Fandrich, M. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell. Mol. Life. Sci., 2007, 64, 2066-2078.
2. Walker, L. C.; LeVine, H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol. Neurobiol., 2000, 21, 83-95.
3. Hardy, J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: "permissive templating" as a general mechanism underlying neurodegeneration. Biochem. Soc. Trans., 2005, 33, 578-581.
4. Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, P. R.; Rimmer, E.; Scazufca, M. Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366, 2112-2117.
5. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug. Disc., 2004, 3, 301-317.
6. Whittle, P. J.; Blundell, T. L. Protein structure--based drug design Annu. Rev. Biophys. Biomol. Struct. 1994, 23, 349-375.
7. Parraga, J.; Cabedo, N.; Andujar, S.; Piqueras, L.; Moreno, L.; Galan, A.; Angelina, E.; Enriz, R. D.; Ivorra, M. D.; Sanz, M. J.; Cortes, D. 2, 3, 9-and 2, 3, 11-trisubstituted tetrahydroproto berberines as D2 dopaminergic ligands. Eur. J. Med. Chem. 2013, 68, 150-166.
8. Tosso, R. D.; Andujar, S. A.; Gutierrez, L.; Angelina, E.; Rodriguez, R.; Nogueras, M.; Baldoni, H.; Suvire, F. D.; Cobo, J.; Enriz, R. D. Molecular modeling study of dihydrofolate reductase inhibitors. Molecular dynamics simulations, quantum mechanical calculations, and experimental corroboration. J. Chem. Inf. Model., 2013, 53, 2018-2032.
9. Andujar, S.; Suvire, F.; Berenguer, I.; Cabedo, N.; Marin, P.; Moreno, L.; Dolores Ivorra, M.; Cortes, D.; Enriz, R. D. Tetrahydroisoquinolines acting as dopaminergic ligands. A molecular modeling study using MD simulations and QM calculations. J. Mol. Model, 2012, 18, 419-431.
10. Andujar, S. A.; Tosso, R. D.; Suvire, F. D.; Angelina, E.; Peruchena, N.; Cabedo, N.; Cortes, D.; Enriz, R. D. Searching the "biologically relevant" conformation of dopamine: a computational approach. J. Chem. Inf. Model., 2012, 52, 99-112.
11. Citron, M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug. Discov., 2010, 9, 387-398.
12. Mc Donald, R. J.; Craig, L.; Hong, N. The etiology of age-related dementia is more complicated than we think. Behav. Brain Res., 2010, 214, 3-11.
13. Benilova, I.; Karran, E.; De Strooper, B. The toxic A]]oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci., 2012, 15, 349-357.
14. Armstrong, R. A. The pathogenesis of Alzheimer's disease: a reevaluation of the "Amyloid Cascade Hypothesis. " Int. J. Alzheimers Dis., 2011, 2011: 630865.
15. Gutierrez, L. J.; Enriz, R. D.; Baldoni, H. A. Structural and thermodynamic characteristics of the exosite binding pocket on the human BACE1: a molecular modeling approach. J. Phys. Chem. A, 2010, 114, 10261-10269.
16. Atwal, J. K.; Chen, Y.; Chiu, C.; Mortensen, D. L.; Meilandt, W. J.; Liu, Y.; Heise, C. E.; Hoyte, K.; Luk, W.; Lu, Y.; Peng, K.; Wu. P.; Rouge, L.; Zhang, Y.; Lazarus, R. A.; Scearce-Levie,. K.; Wang, W.; Wu, Y.; Tessier-Lavigne, M.; Watts, R. J. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Transl. Med, 2011, 3, 84-84.
17. Zhou, L.; Chavez-Gutierrez, L.; Bockstael, K.; Sannerud, R.; Annaert, W.; May, P. C.; Karran, E.; De Strooper, B. Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J. Biol. Chem., 2011, 286, 8677-8687.
18. Ghosh, A. K.; Shin, D. W.; Downs, D.; Koelsch, G.; Lin, X. L.; Ermolieff, J.; Tang, J. Design of potent inhibitors for human brain memapsin 2 (β-Secretase), J. Am. Chem. Soc., 2000, 122, 3522-3523.
19. Tang, J.; Hong, L.; Ghosh, A. K. Aspartic Acid Proteases as Therapeutic Targets. Wiley-VCH, 2010, 45, 413-440.
20. Roberts, B. E.; Shorter, J. Escaping amyloid fate. Nat. Struct. Mol. Biol., 2008, 15, 544-546.
21. Wang, W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm., 2005, 289, 1-30.
22. Bartolini, M.; Andrisano, V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem., 2010, 11, 1018-1035.
23. Esteras-Chopo, A.; Pastor, M. T.; Serrano, L.; Lopez de la Paz, M. New strategy for the generation of specific D-peptide amyloid inhibitors. J. Mol. Biol., 2008, 377, 1372-1381.
24. Fradinger, E. A.; Monien, B. H.; Urbanc, B.; Lomakin, A.; Tan, M.; Li, H.; Spring, S. M.; Condron, M. M.; Cruz, L.; Xie, C. W.; Benedek, G. B.; Bitan, G. C-terminal peptides coassemble into Aβ42 oligomers and project neurons against Aβ42-induced neurotoxicity. Proc. Natl. Acad. Sci. USA, 2008, 105, 14175-14180.
25. Doig, A. J. Peptide inhibitors of β-amyloid aggregation. Curr. Opin. Drug Discov. Devel., 2007, 10, 533-539.
26. Cheng, P. N.; Liu, C.; Zhao, M.; Eisenberg; D.; Nowick, J. S. Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat. Chem., 2012, 4, 927-933.
27. van Groen, T.; Wiesehan, K.; Funke, S. A.; Kadish; I.; Nagel-Steger, L.; Willbold, D. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. Chem. Med. Chem., 2008, 3, 1848-1852.
28. Belluti, F.; Rampa, A.; Gobbi, S.; Bisi, A. Small-molecule inhibitors/ modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease-A patent review (2010-2012). Expert. Opin. Ther. Pat., 2013, 23, 581-596.
29. Re, F.; Airoldi, C., Zona, C.; Masserini, M.; La Ferla, B.; Quattrocchi, N. β amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease. Curr. Med. Chem., 2010, 17, 2990-3006.
30. Bertoncini, C. W.; Jung, Y. S.; Fernandez, C. O.; Hoyer, W.; Griesinger, C.; Jovin, T. M.; Zweckstetter, M. Release of long-range tertiary interactions potentiates aggregation of natively unstructured α-synuclein. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 1430-1435.
31. Dedmon, M. M.; Lindorff-Larsen, K.; Christodoulou, J.; Vendruscolo, M.; Dobson, C. M. Mapping long-range interactions in rsynuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc., 2005, 127, 476-477.
32. Mukrasch, M. D.; Markwick, P.; Biernat, J.; von Bergen, M.; Bernado, P.; Griesinger, C.; Mandelkow, E.; Zweckstetter, M.; Blackledge, M. Highly populated turn conformations in natively unfolded tau protein identified from residual dipolar couplings and molecular simulation. J. Am. Chem. Soc., 2007, 129, 5235-5343.
33. Teplow, D. B.; Lazo, N. D.; Bitan, G.; Bernstein, S.; Wyttenbach, T.; Bowers, M. T.; Baumketner, A.; Shea, J. E.; Urbanc, B.; Cruz, L.; Borreguero, J.; Stanley, H. E. Elucidating amyloid beta-protein folding and assembly: a multidisciplinary approach. Acc. Chem. Res., 2006, 39, 635-645.
34. Soto, C.; Estrada, L. D.; Protein misfolding and neurodegeneration. Arch. Neurol., 2008, 65, 184-189.
35. Zhu, M.; De Simone, A.; Schenk, D.; Toth, G.; Dobson, C. M.; Vendruscolo, M. Identification of small-molecule binding pockets in the soluble monomeric form of the Ab42 peptide. J. Chem. Phys., 2013, 139, 035101.
36. Lemkul, J.; Bevan, D. R. Morin inhibits the early stages of amyloid β-peptide aggregation by altering tertiary and quaternary interactions to produce "off-pathway" structures. Biochemistry, 2012, 30, 5990-6009.
37. Hou, L. M.; Shao, H. Y.; Zhang, Y. B.; Li, H.; Menon, N. K.; Neuhaus, E. B.; Brewer, J. M.; Byeon, I. J. L.; Ray, D. G.; Vitek, M. P.; Iwashita, T. R.; Makula, A.; Przybyla, A. B.; Zagorski, M. G. Solution NMR studies of the A-beta(1-40) and A-beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J. Am. Chem. Soc., 2004, 126, 1992-2005.
38. Zhang, S.; Iwata, K.; Lachenmann, M. J.; Peng, J. W.; Li, S.; Stimson, E. R.; Lu, Y.; Felix, A. M.; Maggio, J. E.; Lee, J. P. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J. Struct. Biol., 2000, 130, 130-141.
39. Kassler, K.; Horn, A. H. C.; Sticht, H. Effect of pathogenic mutations on the structure and dynamics of Alzheimer's A-beta 42-amyloid oligomers. J. Mol. Model., 2010, 16, 1011-1020.
40. Kittner, M.; Knecht, V. J. Disordered versus fibril-like amyloid beta (25-35) dimers in water: structure and thermodynamics. J. Phys. Chem. B, 2010, 114, 15288-15295.
41. Co te S.; Laghaei R.; Derreumaux P.; Mousseau N. Distinct dimerization for various alloforms of the amyloid-beta protein: Aβ1-40, Aβ1-42, and Aβ1-40(D23N). J. Phys. Chem. B., 2012, 116, 4043-4055.
42. Nguyen P.; Derreumaux P. Understanding amyloid fibril nucleation and Aβ oligomer/drug interactions from computer simulations. Acc. Chem. Res., 2014, 47, 603-611.
43. Makin, O. S.; Serpell, L. C. Structures for amyloid fibrils. FEBS J., 2005, 272, 5950-5961.
44. Tycko, R. Solid-state NMR studies of amyloid fibril structure. Annu. Rev. Phys. Chem., 2011, 62, 279-299.
45. Masman, M. F.; Eisel, U. L. M.; Csizmadia, I. G.; Penke, B.; Enriz, R. D.; Marrink, S. J.; Luiten, P. G. M. In silico study of full-length amyloid β 1-42 tri-and penta-oligomers in solution. J. Phys. Chem. B., 2009, 113, 11710-11719.
46. Barrera Guisasola, E. E.; Andujar, S. A.; Hubin, E.; Broersen, K.; Mendez, L.; Delpiccolo, C. M. L; Masman, M. F.; Rodriguez, A. M.; Enriz, R. D. New mimetic peptides inhibitors of AEEaggregation. Molecular guidance for rational drug design. Eur. J. Med. Chem., 2015 (submitted for publication).
47. Andujar, S. A.; Lugli, F.; Hofinger, S.; Enriz, R. D.; Zerbetto, F. Amyloid-b fibril disruption by C60-molecular guidance for rational drug design. Phys. Chem. Chem. Phys., 2012, 14, 8599-8607.
48. Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 2010, 31, 455-461.
49. Luhrs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Dobeli, H. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA., 2005, 102, 17342-17347.
50. Zhao, J. H.; Liu, H. L.; Elumalai, P.; Chen, W. H.; Men L. C.; Liu, K. T. Molecular modeling to investigate the binding of congo red toward GNNQQNY protofibril and in silico virtual screening for the identification of new aggregation inhibitors. J. Mol. Model., 2013, 19, 151-62.
51. Harris, R.; Olson, A. J.; Goodsell, D. S. Automated prediction of ligand-binding sites in proteins. Proteins, 2008, 70, 1506-1517.
52. Hoffmann, R. D. Pharmacophores and pharmacophore searches, Wiley-VCH, 2006, Vol. 32.
53. Elser, W. P.; Stimson, E. R.; Ghilardi, J. R.; Vinters, H. V.; Lee, J. P.; Mantyh, P. W.; Maggio J. E. In vitro growth of Alzheimer's disease β-amyloid plaques displays first-order kinetics. Biochemistry, 1996, 35, 749-757.
54. Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters C. L.; Beyreuther, K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol., 1992, 20, 460-473.
55. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys., 1983, 79, 926-935.
56. Case, D. A.; Cheatham, T. E.; Darden, T.; Gohlke, H.; Luo, R.; Merz Jr., K. M.; Onufriev, A.; Simmerling, C.; Wang B.; Woods, R. J. The Amber biomolecular simulation programs. J. Comput. Chem., 2005, 26, 1668-1688.
57. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An N log(N) method for Ewald sums in large systems J. Chem. Phys., 1993, 98, 10089-10092.
58. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A smooth particle mesh Ewald method. J. Chem. Phys., 1995, 103, 8577-8593.
59. Ryckaert, J.; Ciccotti, G.; Berendsen, H. J. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys., 1977, 23, 327-341.
60. Wiggers, H. J.; Rocha, J. R.; Cheleski, J.; Montanari C. Integration of ligand-and target-based virtual screening for the discovery of cruzain inhibitors. Mol. Inform., 2011, 30, 565-578.
61. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers J.; Davies, M.; Hersey, A. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids. Res., 2012, D1100-D1107.
62. Byun, J. H.; Kim, H.; Kim, Y.; Mook-Jung, I.; Kim, D. J.; Lee, W. K,.; Yoo, K. H. Aminostyrylbenzofuran derivatives as potent inhibitors for Abeta fibril formation. Bioorg. Med. Chem. Lett., 2008, 18, 5591-5593.
63. Shan, W.-J.; Huang, L.; Zhou, Q.; Meng, F.-C.; Li, X.-S. Synthesis, biological evaluation of 9-N-substituted berberine derivatives as multi-functional agents of antioxidant, inhibitors of acetyl cholinesterase, butyrylcholinesterase and amyloid-β aggregation. Eur. J. Med. Chem., 2011, 46, 5885-5893.
64. Zhou, Y.; Jiang, C.; Zhang, Y.; Liang, Z; Liu, W.; Wang, L.; Luo, C,; Zhong, T.; Sun, Y.; Zhao, L.; Xie, X.; Jiang, H.; Zhou, N.; Liu D.; Liu, H.; Structural optimization and biological evaluation of substituted bisphenol A derivatives as beta-amyloid peptide aggregation inhibitors. J. Med. Chem., 2010, 53, 5449-5466.
65. Miyamae, Y.; Kurisu, M.; Murakami, K.; Han, J.; Isoda, H.; Irie, K.; Shigemori, H.; Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein. Bioorg. Med. Chem., 2012, 20, 5844-5849.
66. Chen, S. Y.; Chen, Y.; Li, Y. P.; Chen, S. H.; Tan, J. H.; Ou T. M.; Gu, L. Q.; Huang, Z. S. Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease. Bioorg. Med. Chem., 2011, 19, 5596-5604.
67. Carver, J.; Duggan, P. J.; Ecroyd, H.; Liu, Y.; Meyer, A. G.; Tranberg, C. E. Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation. Bioorg. Med. Chem., 2010, 18, 222-228.
68. Li, S. Y.; Wang, X. B.; Xie, S. S.; Jiang, N.; Wang, K. D.; Yao, H. Q.; Sun, H. B., Kong, L. Y. Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 2013, 69, 632-646.
69. Di Santo, R.; Costi, R.; Cuzzucoli, G.; Pescatori, L.; Rosi, F.; Scipione, L.; Celona, D.; Vertechy, M.; Ghirardi, O.; Piovesan, P.; Marzi, M.; Caccia, S.; Guiso, G.; Giorgi, F.; Minetti, P. Design, synthesis, and structure-activity relationship of N-aryl naphthylamine derivatives as amyloid aggregation inhibitors. J. Med. Chem., 2012, 55, 8538-8548.
70. Catto, M.; Aliano, R.; Carotti, A.; Cellamare, S.; Palluotto, F.; Purgatorio, R.; De Stradis, A. Campagna F. Design, synthesis and biological evaluation of indane-2-arylhydrazinylmethylene-1, 3-diones and indol-2-aryldiazenylmethylene-3-ones as beta-amyloid aggregation inhibitors. Eur. J. Med. Chem., 2010, 45, 1359-1366.
71. Campagna, F.; Catto, M.; Purgatorio, R.; Altomare, C. D.; Carotti, A.; De Stradis, A.; Palazzo, G. Synthesis and biophysical evaluation of arylhydrazono-1H-2-indolinones as β-amyloid aggregation inhibitors. Eur. J. Med. Chem., 2011, 46, 275-284.
72. Simons, L. J.; Caprathea, B. W.; Callahana, M.; Grahama, J. M.; Kimurab, T.; Laia, Y.; LeVine, H.; Lipinskia, W.; Sakkaba, A. T.; Tasakib, Y.; Walkera, L. C.; Yasunagab, T.; Yea, Y.; Zhuanga, N.; Augelli-Szafrana, C. E. The synthesis and structure-activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 654-657.
73. Kwon, Y. E.; Park, J. Y.; No, K. T.; Shin, J. H.; Lee, S. K.; Eun, J. S.; Yang, J. H.; Shin, T. Y.; Kim, D. K.; Chae, B. S.; Leem, J. Y.; Kim, KH. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Bioorg. Med. Chem., 2007, 15, 6596-6607.
74. Prati, F.; Bartolini, M.; Simoni, E.; De Simone, A.; Pinto, A.; Andrisano, V.; Bolognesi, M. L. Quinones bearing non-steroidal antiinflammatory fragments as multitarget ligands for Alzheimer's disease. Bioorg. Med. Chem. Lett., 2013, 23, 6254-6258.
75. Gasteiger, J.; Marsili, M.; Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron, 1980, 36, 3219-3228.
76. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. Autodock4 and AutoDock-Tools4: automated docking with selective receptor flexiblity. J. Comput. Chem., 2009, 16, 2785-91.
77. O'Boyle, N. M.; Banck, M.; James, C. A.; Morley, C.; Vandermeersch, T.; Hutchison, G. R. Open Babel: An open chemical toolbox. J. Cheminf., 2011, 3, 33.
78. Sing, T.; Sander, O.; Beerenwinkel, N.; Lengauer, T. ROCR: visualizing classifier performance in R. Bioinformatics, 2005, 21, 3940-3941.
79. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http: //www. R-project. org/.
80. Becke, AD. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys. Rev. A., 1988, 38, 3098-3100.
81. Lee, C.; Yang, W.; Parr, R. G.; Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B, 1988, 37, 785-789.
82. Grimme, S.; Semiempirical GGA-type density functional constructed with a long-range dispersion correction. J. Comp. Chem., 2006, 27, 1787-1799.
83. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc., 1995, 117, 5179-5197.
84. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field. J. Comput. Chem., 2004, 25, 1157-1174.
85. Bader, R. F. W. Atoms in molecules. Acc. Chem. Res., 1985, 18, 9-15.
86. Lu, T.; Chen, F. Multiwfn: a multifunctional wave-function analyzer. J. Comput. Chem., 2012, 33, 580-592.
87. Lemkul, J.; Bevan, D. R. Assessing the stability of Alzheimer's amyloid protofibrils using molecular dynamics. J. Phys. Chem. B, 2010, 114, 1652-1660.
88. Lemkul, J.; Bevan, D. R. Destabilizing Alzheimer's Aβ42 protofibrils with morin: mechanistic insights from molecular dynamics simulations. Biochemistry, 2010, 49, 3935-3946.